Better Buy: Editas Medicine vs. Intellia
CRISPR stands for Clustered, Regularly Interspaced, Short Palindromic Repeats. It is an emerging gene-editing technology that can rapidly locate and change genome sequences to deliver a cure for certain hereditary diseases. Since CRISPR was discovered in 1987 by Japanese researchers, the technology has taken the biotech industry by storm.
Indeed, two companies that focus on CRISPR therapies, Editas Medicine (NASDAQ: EDIT) and Intellia (NASDAQ: NTLA), have achieved more than $1 billion in market capitalization despite having candidates in the infant stages of the clinical trial process. Today's let's take a look at which of the two companies is a better choice for biotech investors.
Image source: Getty Images.
Source Fool.com
